ORTHO-NOVUM 7/7/7-28
LOE ApproachingNDAORAL-28TABLET
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 7/7/7-28 is an oral contraceptive tablet containing norethindrone and ethinyl estradiol in a 28-day cycle formulation. It prevents pregnancy through hormonal suppression of ovulation and cervical mucus thickening. This is a classic combination oral contraceptive used for decades in women's health.
LOE Approaching
As LOE approaches, the brand team is likely contracting; roles focus on managed care retention and generic transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 7/7/7-28 involves managing a legacy contraceptive brand in decline, focusing on payer negotiations, generic defense, and portfolio transition strategy. Career growth is limited; this role suits those seeking operational expertise in LOE management or those early in commercial pharmacy careers.
Brand ManagerProduct Manager
Worked on ORTHO-NOVUM 7/7/7-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.